BioNTech Future Growth

Future criteria checks 1/6

BioNTech's earnings are forecast to decline at 4.6% per annum while its annual revenue is expected to grow at 7.1% per year. EPS is expected to decline by 2.5% per annum. Return on equity is forecast to be -3% in 3 years.

Key information

-4.6%

Earnings growth rate

-2.5%

EPS growth rate

Biotechs earnings growth34.8%
Revenue growth rate7.1%
Future return on equity-3.0%
Analyst coverage

Good

Last updated09 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

XTRA:22UA - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,723-768-62351615
12/31/20252,678-678-90447019
12/31/20242,672-6323602,16819
6/30/20242,691-5042,3522,972N/A
3/31/20242,7301134,9445,732N/A
12/31/20233,8199304,6665,371N/A
9/30/20236,6182,7514,6905,350N/A
6/30/20239,1844,3758,7269,317N/A
3/31/202312,2136,2388,4938,850N/A
12/31/202217,3119,43413,21413,577N/A
9/30/202218,56510,32212,27712,549N/A
6/30/202221,19111,7489,0409,271N/A
3/31/202223,30312,8635,0665,251N/A
12/31/202118,97710,293736890N/A
9/30/202113,7907,4931,1981,338N/A
6/30/20217,7704,072-474-355N/A
3/31/20212,5031,197-376-270N/A
12/31/202048215-99-13N/A
9/30/2020165-410-382-326N/A
6/30/2020126-230-239-183N/A
3/31/2020110-192-268-222N/A
12/31/2019109-179-270-198N/A
9/30/2019144-122-220-138N/A
6/30/2019136-116-142-75N/A
3/31/2019132-77-136-55N/A
12/31/2018128-48-126-59N/A
12/31/201762-86N/A-53N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 22UA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 22UA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 22UA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 22UA's revenue (7.1% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 22UA's revenue (7.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 22UA is forecast to be unprofitable in 3 years.


Discover growth companies